Fierce Pharma:Tiny biotech Errant sues Bluebird for patent infringement in developing gene therapy LentiGlobin

The ongoing battle between gene therapy biotechs Bluebird Bio and Errant has finally reached the patent infringement stage.

Last week, in U.S. District Court in Delaware, Errant Gene Therapeutics, a tiny Chicago company, filed a lawsuit alleging that Bluebird of Massachusetts infringed its patents for a recombinant vector used in the manufacture of the treatment of two rare blood disorders.

View the rest of the article here

View the PDF